Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NLRC4-MAS”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Large-scale testing (Phase 3)Study completedNCT03512314
What this trial is testing

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

Who this might be right for
XIAP DeficiencyNLRC4-MAS
AB2 Bio Ltd. 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT04641442
What this trial is testing

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Who this might be right for
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
Novartis Pharmaceuticals 17
Not applicableLooking for participantsNCT02974595
What this trial is testing

Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)

Who this might be right for
NOMIDDIRANLRC4-MAS+2 more
National Institute of Allergy and Infectious Diseases (NIAID) 3,200
Large-scale testing (Phase 3)Study completedNCT03113760
What this trial is testing

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

Who this might be right for
NLRC4-MASXIAP Deficiency
AB2 Bio Ltd. 15